

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/049,893
Filing Date	July 22, 2002
First Named Inventor	David Stern
Art Unit	1649
Examiner Name	G. Emch
Attorney Docket Number	59472-A-PCT-US

Attorney Docket Number 59472-A-PCT-US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: David Stem et al.

Applicants. David Stein
Serial No. 10/049,893

Serial No.: 10/519,3
Filed: July 22 2002

Filed: July
Exhibit B

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/049,893
		Filing Date	July 22, 2002
		First Named Inventor	David Stern
		Art Unit	1649
		Examiner Name	G. Emch
Sheet	2	of	2
		Attorney Docket Number	
		59472-A-PCT-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hale, K. et al. "Multifunctional Regulation of the Biological Effects of TNF- α by the Soluble Type I and Type II TNF Receptors," Cytokine 7(1):26-38 (1995)	
		Hardy, J. "The Alzheimer family of diseases: Many etiologies, one pathogenesis?" PNAS 90:2095-2097 (1997)	
		Heaney, M., et al. "Soluble Hormone Receptors," Blood 82(7):1945-1948 (1993)	
		Hsiao, K., et al. "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," Science 274:99-102 (1996)	
		Miyata, T., et al. "The Receptor for Advanced Glycation End Products (RAGE) is a Central Mediator of the Interaction of AGE- β 2 ..." J. Clin. Invest. 98(5):1088-1094 (1996)	
		Picciotto, M., "Using Knockout and Transgenic Mice to Study Neurophysiology and Behavior," Physiol. Review 78:1131-1163 (1998)	
		Schenk, D., et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature 400:173-177 (1999)	
		Weggen, et al., "A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity," Nature 414:212-216 (2001)	
		Pending Claims of U.S. Application Serial No. 11/805,164, filed May 21, 2007	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.